Is PFE a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

23,051 people get PFE articles and Market Currents by email alert.

Get email alerts on PFE »

HEADLINES:

Another Look At Marketing Vs. R&D In Pharma
Derek Lowe • Thu, May 23 • 2 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Thu, May 23
Cramer's Mad Money - The Miraculous Six Flags (5/22/13)
SA Editor Miriam Metzinger • Thu, May 23
Is There Value In Today's Stock Market?
William Smead • Wed, May 22 • 3 Comments
Pfizer Announces Plan for Split-Off of Zoetis

Business Wire (Wed, 8:00AM)
AbbVie Reaches New Highs Thanks To Humira
Efsinvestment • Wed, May 22 • 5 Comments
Pricing A Highly Probable Takeover Of MannKind
George Rho • Wed, May 22 • 61 Comments
The Ulcerative Colitis Game Of Thrones
Cory Renauer • Tue, May 21 • 3 Comments
American Society Of Clinical Oncology Abstracts Point To Potential Profits
David Greene • Tue, May 21 • 2 Comments
Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility

Business Wire (Mon, 5:01PM)
Catalyst Pharmaceutical's CPP-115 May Be Big Pipeline In Just One Little Pill
Michael_Anderson • Mon, May 20 • 2 Comments
FDA Painkiller Abuse Concerns Creating Opportunity For Pfizer
Cory Renauer • Mon, May 20 • 2 Comments
Shades Of 1999
George Acs • Sun, May 19 • 24 Comments
Oramed Sweeps Past Worldwide Giants With The First Trial Of Orally Delivered Insulin
Sharon di Stefano • Sun, May 19 • 50 Comments
Why MannKind's Afrezza Will Succeed Where Pfizer Failed
Cory Renauer • Sat, May 18 • 30 Comments
13F Watch: Funds Add Healthcare And Trim Technology As Activists Take Center Stage
CFA Institute Contributors • Thu, May 16
Antares: Reiteration Of My Buy Recommendation
Smith On Stocks • Thu, May 16 • 17 Comments
The Dow Hits All-Time Highs, But The Truth Is It Remains Cheaply Valued
Chuck Carnevale • Thu, May 16 • 62 Comments
Large Hedge Fund Levin Capital's Top Stock Picks
Insider Monkey • Wed, May 15
Organovo: Get Rich Or Die Tryin'
Douglas W. House • Wed, May 15 • 42 Comments

To learn more about Seeking Alpha Pro, click here.

Pfizer's Direct-To-Consumer Campaigns: A Model For The Future?
Peter Geschek • Mon, May 13 • 2 Comments
An Update On Pfizer's Recently Approved Drugs
Jon Crowley • Tue, May 7 • 8 Comments
Pssstt! Pfizer Is Not Executing And Is Overvalued
Deep Dives • Tue, Apr 30 • 11 Comments
Whisper Number Impact: Earnings Preview For Pfizer
WhisperNumber • Mon, Apr 29 • 1 Comment
Enbrel's Asian Biosimilar Competitors
Peter Geschek • Fri, Apr 26 • 1 Comment
Can Pfizer Keep Up The Positive Momentum?
WM Analyst • Thu, Apr 18 • 4 Comments
Pfizer: Why You Should Be Cautious Now
Stock Gamer • Mon, Apr 15 • 7 Comments
Pfizer's New Breast Cancer Drug Could Be A Game Changer
StockBaller • Mon, Apr 15 • 4 Comments
Reasons For A Bullish Stance On Pfizer
StockRiters • Thu, Apr 11 • 2 Comments
FDA Designation May Accelerate Palbociclib Timeline But Not Increase Approval Probability
Deep Dives • Thu, Apr 11 • 3 Comments
Where Is Pfizer Heading With The Patent Cliff?
Emerging Equities • Tue, Apr 9 • 4 Comments
Pfizer's Oncology Division Gets A Boost With European Approval For Bosulif
Trefis • Fri, Apr 5
A Critical Analysis Of Pfizer's Pipeline, Earnings And Valuation
Deep Dives • Fri, Apr 5 • 19 Comments
Pfizer's Prevnar 13: The World's Leading Vaccine And Its Competitors
Peter Geschek • Thu, Apr 4
Biosimilars Could Be An Unlikely Boost For Pfizer
Jon Crowley • Wed, Apr 3 • 4 Comments
Pfizer May Have To Rethink Xalkori Cost Structure
John Mylant • Fri, Mar 29 • 13 Comments
Pfizer's Next Big Deal Will Generate Income For Novartis, Prevent Competitors' Initiative
Jean-Christophe Larsimont • Thu, Mar 28 • 12 Comments
Lyrica's New Role Could Pay Off Big For Pfizer Investors
Stock Maelstrom • Thu, Mar 28 • 3 Comments
Pfizer Predicted To 'Substantially Underperform' The Market
David Pinsen • Wed, Mar 27 • 11 Comments
Is Pfizer Overvalued At $28.5?
Bio Vantage • Wed, Mar 27 • 10 Comments

Another Look At Marketing Vs. R&D In Pharma
Derek Lowe • Thu, May 23 • 2 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Thu, May 23
Cramer's Mad Money - The Miraculous Six Flags (5/22/13)
SA Editor Miriam Metzinger • Thu, May 23
Is There Value In Today's Stock Market?
William Smead • Wed, May 22 • 3 Comments
AbbVie Reaches New Highs Thanks To Humira
Efsinvestment • Wed, May 22 • 5 Comments
Pricing A Highly Probable Takeover Of MannKind
George Rho • Wed, May 22 • 61 Comments
The Ulcerative Colitis Game Of Thrones
Cory Renauer • Tue, May 21 • 3 Comments
American Society Of Clinical Oncology Abstracts Point To Potential Profits
David Greene • Tue, May 21 • 2 Comments
Catalyst Pharmaceutical's CPP-115 May Be Big Pipeline In Just One Little Pill
Michael_Anderson • Mon, May 20 • 2 Comments
FDA Painkiller Abuse Concerns Creating Opportunity For Pfizer
Cory Renauer • Mon, May 20 • 2 Comments
Shades Of 1999
George Acs • Sun, May 19 • 24 Comments
Oramed Sweeps Past Worldwide Giants With The First Trial Of Orally Delivered Insulin
Sharon di Stefano • Sun, May 19 • 50 Comments
Why MannKind's Afrezza Will Succeed Where Pfizer Failed
Cory Renauer • Sat, May 18 • 30 Comments
13F Watch: Funds Add Healthcare And Trim Technology As Activists Take Center Stage
CFA Institute Contributors • Thu, May 16
Antares: Reiteration Of My Buy Recommendation
Smith On Stocks • Thu, May 16 • 17 Comments
The Dow Hits All-Time Highs, But The Truth Is It Remains Cheaply Valued
Chuck Carnevale • Thu, May 16 • 62 Comments
Large Hedge Fund Levin Capital's Top Stock Picks
Insider Monkey • Wed, May 15
Organovo: Get Rich Or Die Tryin'
Douglas W. House • Wed, May 15 • 42 Comments
10 Hot Healthcare Dogs Probe 6% To 38.2% Gains In April
Fredrik Arnold • Mon, May 13 • 2 Comments
Baby Boomers Are Money-Making Machines For Big Pharma
Tedra DeSue • Mon, May 13 • 2 Comments

Pfizer's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Tue, Apr 30
Pfizer's CEO Presents at Annual Shareholder Meeting Conference (Transcript)
Fri, Apr 26 • 5 Comments
Pfizer's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Jan 29
Pfizer's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 1, 2012 • 1 Comment
Pfizer's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Jul 31, 2012 • 2 Comments
Pfizer's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Tue, May 1, 2012
Pfizer's CEO Hosts 2012 Annual Meeting (Transcript)
Thu, Apr 26, 2012 • 2 Comments
Pfizer's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Tue, Jan 31, 2012 • 1 Comment
Pfizer's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Tue, Nov 1, 2011
Pfizer's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Tue, Aug 2, 2011
Pfizer's CEO Discusses Q1 2011 Results - Earnings Call Transcript
Tue, May 3, 2011 • 1 Comment
Pfizer's CEO Discusses Q4 2010 Results - Earnings Call Transcript
Tue, Feb 1, 2011 • 1 Comment
Pfizer CEO Discusses Q3 2010 Results - Earnings Call Transcript
Tue, Nov 2, 2010
Pfizer Q2 2010 Earnings Call Transcript
Tue, Aug 3, 2010
Pfizer Q1 2010 Earnings Call Transcript
Tue, May 4, 2010
Pfizer Inc. Q4 2009 Earnings Call Transcript
Wed, Feb 3, 2010
Pfizer, Inc. Q3 2009 Earnings Call Transcript
Tue, Oct 20, 2009
Pfizer Inc. Q2 2009 Earnings Call Transcript
Wed, Jul 22, 2009
Pfizer Q1 2009 Earnings Call Transcript
Tue, Apr 28, 2009
Pfizer Q4 2008 Earnings and Conference Call Transcript
Wed, Jan 28, 2009

Stocks Tumble Nearly 1% on Fed Tapering Fears

at CNBC.com (Wed, 4:08PM)
Stocks Rally as Bernanke Defends Aggressive Fed Easing

at Fox Business (Wed, 10:13AM)
Pfizer Announces Plan for Split-Off of Zoetis

Business Wire (Wed, 8:00AM)
Futures Tick Up; Fed News on Tap

at Fox Business (Wed, 7:27AM)
Stocks Climb on Dovish Fed Comments; Bernanke Up Next

at CNBC.com (Tue, 4:07PM)
Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility

Business Wire (Mon, 5:01PM)
Final Trade: Your First Move for Wednesday, May 15

at CNBC.com (May 14, 2013)
Pfizer Announces 11 Abstracts for Tofacitinib to Be Presented at the European League Against Rheumatism (EULAR) 2013 Annual Meeting

Business Wire (May 13, 2013)
Movers & Shakers: Friday’s movers: Tesla, Groupon notch weekly gains

at MarketWatch.com (May 10, 2013)
Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Business Wire (May 8, 2013)
Stocks Still Cheap? One Pro Says Yes

at CNBC.com (May 6, 2013)
Big Pharma Disappoints on Revenues, Earnings

at CNBC.com (May 6, 2013)
Facing Off Against Counterfeit Online Pharmacies: Pfizer Launches New Purchasing Website To Help Alleviate the Guesswork Around Buying Legitimate Viagra® (sildenafil citrate) Online

Business Wire (May 6, 2013)
Early Movers: TSN, PFE, JPM & More

at CNBC.com (May 6, 2013)
Fear on the Floor Ahead of Jobs Report

at CNBC.com (May 2, 2013)
ING U.S. Debuts in 2nd Biggest IPO of '13

at Fox Business (May 2, 2013)
May's OK, Worry About Later Months: Pro

at CNBC.com (May 1, 2013)
Mark Hulbert: Stay away from sin

at MarketWatch.com (May 1, 2013)
Final Trade: Your First Move for Wednesday, May 1

at CNBC.com (Apr 30, 2013)
Earnings Watch: Updates, advisories and surprises

at MarketWatch.com (Apr 30, 2013)

PFE vs. ETF Alternatives

Company Description

Pfizer Inc. (which may be referred to as Pfizer, the Company, we, us or our) is a research-based, global biopharmaceutical company. We apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in... More

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 22, 11:07 AM AIG remains at the top Goldman's list of hedge fund hotels (the 50 stocks appearing most frequently among hedge fund top 10 holdings). Google (GOOG) retains its #2 position. Apple (APPL) - in the top spot for 3 years until February - remains at #3. Goldman notes the basket has outperformed the S&P a bit this year and the top 20 has done better by more than 1000 basis points. We smell an ETF offering. The rest of the top 20: C, GM, PCLN, VMED, NWSA, MSFT, HTZ, JPM, APC, PFE, QCOM, CHTR, HES, CBS, EBAY, DAL, EQIX. 4 Comments
Wednesday, May 22, 8:18 AM Pfizer (PFE) plans to spin off its remaining stake in Zoetis (ZTS) through a tax-free exchange offer in which Pfizer owners can exchange their Pfizer shares for stock in Zoetis owned by Pfizer (got that?). Pfizer has received a waiver of the 180-day lock-up from the book runners of the Zoetis IPO. PFE +2.1%, ZTS -1.2% premarket. (PR) 9 Comments [Healthcare, Breaking News, On the Move]
Monday, May 20, 5:23 PM Pfizer (PFE) says it's discontinuing Phase 3 studies on its investigational compound inotuzumab ozogamicin in combination with rituximab, a treatment for patients with non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy, after the study failed to meet its primary objective of improving overall survival. No new or unexpected safety issues were identified, and PFE says it's continuing to review the the drug for potential subset applications. Shares -0.3% AH. Comment! [Healthcare]
Friday, May 10, 8:12 AM Pain Therapeutics (PTIE) craters 45.5% in premarket trading after Pfizer (PFE) says it is "considering its options" on Remoxy and may not respond to the FDA's complete response letter anytime in the next two years. PTIE sub-licensed Remoxy's commercialization rights to PFE subsidiary King Pharma (I, II). Comment! [Healthcare, On the Move]
Friday, May 10, 7:46 AM Pfizer (PFE) updates Durect (DRRX) on Remoxy, saying that it's "considering its options", and that if it elects to continue development of Remoxy, "we would not expect to submit a response to the "complete response" letter before mid-2015." (PR) This is less positive than expected by SA author Jason Napodano; shares are -12.6% premarket. 1 Comment [Healthcare, On the Move, Breaking News]
Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
Monday, May 6, 9:38 AM More on Pfizer (PFE -0.5%): A plan by the company to sell Viagra online is motivated by the estimated hundreds of millions of dollars it loses to counterfeit versions of the drug found online. A ticking clock for patent expiration (2020) in the U.S. could also be a factor. To attract new customers, Pfizer will reportedly become more promotional with Viagra by offering three free pills with the first order and then 30% off order number two. 3 Comments [Healthcare]
Monday, May 6, 9:23 AM Pfizer (PFE) plans to start selling Viagra online, according to an AP report. The initiative could serve as a test run by Big Pharma over disrupting its current model to look at online distribution for treatments viewed as more embarrassing to buy in person. Drugstore operators (CVS, WAG, RAD) will be watching the development very carefully. PFE -0.1% premarket. 2 Comments [Healthcare, Consumer]
Tuesday, April 30, 11:41 AM Pain Therapeutics (PTIE +19%) and Durect (DRRX +25.5%) both soar on the back of positive comments out of Pfizer's (PFE) conference call about Remoxy, an oxycodone capsule the pair have been developing. PTIE sub-licensed Remoxy's commercialization rights to King Pharmaceuticals, which is a subsidiary of PFE, and the pharma-giant noted in its call that it's had a productive meeting with the FDA last month regarding the drug. (PFE Conference Call Webcast) 1 Comment [Healthcare, On the Move]
Tuesday, April 30, 7:21 AM More on Pfizer (PFE) Q1 earnings: Sales fell 9% Y/Y - 8% operational, 1% unfavorable fx adjustment. Much of the operational decrease due to loss of exclusivity of Lipitor. Emerging markets revenue +6%. Adjusted cost of sales fell 7%. FY2013 revenue guidance reduced to $55.3B-$57.3B from $56.2B-$58.2B. Adjusted EPS of $2.14-$2.24 from $2.20-$2.30. About $8B in share repurchases YTD, "with significant additional capital expected to be allocated ... for the remainder of the year." Shares -2.2% premarket. Conference call at 10 ET. (PR) 4 Comments [Healthcare, Earnings, On the Move]
Tuesday, April 30, 7:01 AM Pfizer (PFE): Q1 EPS of $0.54 misses by $0.01. Revenue of $13.5B misses by $0.6B. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, April 30, 12:05 AM Notable earnings before Tuesday’s open: ABFS, AET, AGCO, AMED, ARCO, AVP, BEN, BP, CIE, CMI, CNH, COCO, CRIS, CYNO, DBD, DDD, DPZ, ECL, EPD, ESV, EXAS, FCH, FIS, FLWS, GAS, GOV, HCLP, HCP, HEP, HNR, HOT, HRS, HUN, HW, IVZ, KLIC, LM, MCGC, MHP, MLM, MNTA, MPC, MPLX, MSO, MTG, MTOR, MWV, NEE, NI, NYX, ODP, OSK, PBI, PEG, PES, PFE, ROC, SAVE, SIRI, TFX, THC, TRI, TRW, UBS, UDR, VLO, VSH, WEC, X, XYL, ZTS Comment! [Earnings]
Monday, April 29, 5:30 PM Notable earnings before Tuesday’s open: ABFS, AET, AGCO, AMED, ARCO, AVP, BEN, BP, CIE, CMI, CNH, COCO, CRIS, CYNO, DBD, DDD, DPZ, ECL, EPD, ESV, EXAS, FCH, FIS, FLWS, GAS, GOV, HCLP, HCP, HEP, HNR, HOT, HRS, HUN, HW, IVZ, KLIC, LM, MCGC, MHP, MLM, MNTA, MPC, MPLX, MSO, MTG, MTOR, MWV, NEE, NI, NYX, ODP, OSK, PBI, PEG, PES, PFE, ROC, SAVE, SIRI, TFX, THC, TRI, TRW, UBS, UDR, VLO, VSH, WEC, X, XYL, ZTS 1 Comment [Earnings]
Monday, April 29, 8:18 AM Protalix BioTherapeutics (PLX) rises 6% premarket as its Type I Gaucher disease treatment UPLYSO ("ELELYSO" outside of Latin America) gains approval in Mexico and Chile — it is already approved in the U.S., Israel, and Brazil. The company develops and commercializes the drug with Pfizer (PFE). (PR) Comment! [Healthcare, On the Move]
Monday, April 29, 7:55 AM Merck (MRK) and Pfizer (PFE) enter into a 60/40 worldwide agreement to jointly develop and commercialize PFE's type 2 diabetes treatment ertugliflozin which should enter Phase III trials later this year. As part of the deal, PFE received $60M upfront and may receive additional payments in the future. (PR) 3 Comments [Healthcare]
Friday, April 26, 11:12 AM Medivation (MDVN +0.6%) and Astellas Pharma (ALPMF.PK) say the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the oral androgen receptor inhibitor XTANDI (approved in the U.S.) for adult men with progressed metastatic castration-resistant prostate cancer. Other CHMP news: Pfizer's (PFE -1.1%) arthritis pill Xeljanz is rejected (appeal to come), Roche (RHHBY.OB +0.2%) and Curis' (CRIS +4.5%) Erivedge for basal cell carcinoma gets a recommendation, and Vivus' (VVUS +3.7%) ED drug Spedra gets a positive review. (See also: AVNR and CELG get thumbs up from EU regulators) 1 Comment [Healthcare, On the Move]

DAG1996
$PFE looking to add to position on pipeline valuation if dips to $28.00.
4 hours ago
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

m@ximus
huge entry point for late longs on $PFE, 4 blockbusters will put PFE in $33-$35 range in 2013.
Tue, 12:35 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joseph P. Porter
Looks like $PFE isn't ready to stay over $30.00 - should think the div would help there.
Mon, 1:23 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chines33
Top longs from this price $BP $HIG $GILD $DD $FDX $SODA $EOG $WFM $ADT $YUM $SWK $WY $LEN $LNKD $NFLX $HD $EBAY $PFE $KMP $IGT
May 13, 11:09 PM
Reply (7)

• !Report Abuse
View all 7 replies
Chines33: Yes typically. It all depends on situation. Price, company, news, overall market. Lot of variables.
May 14, 12:07 PM
• !Report Abuse
wheelz23: i was swing trading, but have been day trading...it seems like swing trading is less work, more money for the stocks i was trading...thanks
May 14, 12:46 PM
• !Report Abuse
Add a reply...

140 characters

Joseph P. Porter
$PFE making another run to go over $30.00. Maybe they'll manage to stay up there this time - or have they hit the ceiling?
May 13, 11:58 AM
Reply (3)

• !Report Abuse
View all 3 replies
Joseph P. Porter: If they were to get some bad news it might help bring the price down a little bit, but I think last week was their down week.
May 13, 12:52 PM
• !Report Abuse
DAG1996: True, last week was probably $PFE near-term bottom, but might depend more on market-wide movement ... finally feeling toppy short term.
May 13, 12:56 PM
• !Report Abuse
Add a reply...

140 characters

Nefas
Stocks i am watching next week $ZAGG, $MNKD, $HLF, $BBRY, $NOK, $MUX, $NBG, $PTIE, $PFE, $MTG..any suggestions ideas on my watchlist?
May 11, 10:02 AM
Reply (4)

• !Report Abuse
View all 4 replies
Seacap: I'm going to jump all over BBRY past 16.60
May 13, 12:24 AM
• !Report Abuse
Bigisbetter: DDD
May 14, 12:35 PM
• !Report Abuse
Add a reply...

140 characters

Nefas
Am i to latte to the whole Bio/Pharma stuff with $HLF, $MNKD $PFE, $PTIE...i feel like i might be....
May 10, 5:22 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dividend Sheet
$GSK $AEP and $PFE are tomorrow's top ex-dividend stocks - http://stks.co/jUK4 - 2.7% average yield - $UL $PPG $WFC 49 ex-dividend stocks
May 7, 3:23 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Gare17
Check out my article : http://seekingalpha.com/p/137f5 $NVS $MRK $PFE $ZLCS
May 6, 1:08 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

DAG1996
never thought i'd see a day when $T and $PFE are my only holdings in the red on the same day. what a day! i hope both go lower to buy more.
May 3, 12:50 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Chines33
Top longs from this price $BP $HIG $GILD $DD $FDX $SODA $EOG $WFM $ADT $YUM $SWK $WY $LEN $LNKD $NFLX $HD $EBAY $PFE $KMP $IGT
May 13, 11:09 PM
Reply (7)

• !Report Abuse
View all 7 replies
Chines33: Yes typically. It all depends on situation. Price, company, news, overall market. Lot of variables.
May 14, 12:07 PM
• !Report Abuse
wheelz23: i was swing trading, but have been day trading...it seems like swing trading is less work, more money for the stocks i was trading...thanks
May 14, 12:46 PM
• !Report Abuse
Add a reply...

140 characters

Nefas
Stocks i am watching next week $ZAGG, $MNKD, $HLF, $BBRY, $NOK, $MUX, $NBG, $PTIE, $PFE, $MTG..any suggestions ideas on my watchlist?
May 11, 10:02 AM
Reply (4)

• !Report Abuse
View all 4 replies
Seacap: I'm going to jump all over BBRY past 16.60
May 13, 12:24 AM
• !Report Abuse
Bigisbetter: DDD
May 14, 12:35 PM
• !Report Abuse
Add a reply...

140 characters

Joseph P. Porter
$PFE making another run to go over $30.00. Maybe they'll manage to stay up there this time - or have they hit the ceiling?
May 13, 11:58 AM
Reply (3)

• !Report Abuse
View all 3 replies
Joseph P. Porter: If they were to get some bad news it might help bring the price down a little bit, but I think last week was their down week.
May 13, 12:52 PM
• !Report Abuse
DAG1996: True, last week was probably $PFE near-term bottom, but might depend more on market-wide movement ... finally feeling toppy short term.
May 13, 12:56 PM
• !Report Abuse
Add a reply...

140 characters

Gare17
If we don't hear from $ZLCS next Monday or Tuesday with Novartis renewal I think buyout rumors will start .. $NVS $MRK $PFE #Ions
Apr 26, 12:43 PM
Reply (1)

• !Report Abuse
View all 1 replies
Gare17: $ZLCS buyout or spinoff with $NVS for Chts technology
Apr 29, 4:17 PM
• !Report Abuse
Add a reply...

140 characters

Joseph P. Porter
The mixed week in earnings takes its toll today: $CUR, $DCIX, $KKR, $ONTY, $PFE and $RNO all down, even though many gave good news this week
Apr 26, 12:22 PM
Reply (5)

• !Report Abuse
View all 5 replies
neobliviscar: Ja mata. Let me frame it then. The stock is only up +10% this week. It was up +11%, except for that Charlie Sheen Violent Torpedo of Truth.
Apr 26, 1:34 PM
• !Report Abuse
Joseph P. Porter: P.S. I'm long DCIX.
Apr 26, 2:16 PM
• !Report Abuse
Add a reply...

140 characters

Joseph P. Porter
$PFE pfaithfully pfollows its tradition of offering its divs - $0.24 to be paid in June. Pfar out.
Apr 25, 2:32 PM
Reply (3)

• !Report Abuse
View all 3 replies
Joseph P. Porter: Absolutely pfabulous, in my book. Pfizer is to dividends what prunes are to BM's - regularity exemplified. $PFE is pfar and away the best
Apr 25, 9:53 PM
• !Report Abuse
Joseph P. Porter: company I have shares in. So pfar, more than 30% return, not counting divs. Pfortunately, I bought in over a year ago.
Apr 25, 9:55 PM
• !Report Abuse
Add a reply...

140 characters

The Hammer
$PFE breaking out multi-year highs. Lots of investors jumped ship early on this one. It is getting close to oversold. how far does this run?
Jan 9, 4:10 PM
Reply (6)

• !Report Abuse
View all 6 replies
The Hammer: Broke above $30 nice. however the pure pharma business model is riskier than the nvs or jnj model more preferred. Hope it runs fast
Apr 11, 9:57 AM
• !Report Abuse
The Hammer: will lighten up into a nice spike from here. reinvested every div over something like 7 years or so.
Apr 11, 9:58 AM
• !Report Abuse
Add a reply...

140 characters

Chines33
$PFE ftw!!!!!!!!
Apr 10, 3:45 PM
Reply (4)

• !Report Abuse
View all 4 replies
Chines33: Only 1 of 2 longs I've had for over a year. Largest position still.
Apr 10, 3:56 PM
• !Report Abuse
bd4uandu: Glad you clarified that in other circles it has other meanings.
Apr 10, 3:58 PM
• !Report Abuse
Add a reply...

140 characters

m@ximus
sold $SPY and got into $PFE long. is this an ongoing fractional Correction?
Apr 5, 2:44 PM
Reply (2)

• !Report Abuse
View all 2 replies
Joseph P. Porter: From Bloomberg - it sounds as if the "correction" could become a Q2-long phenomenon, depending on earnings. They will have to pry $PFE out
Apr 8, 5:51 PM
• !Report Abuse
Joseph P. Porter: of my cold, dead hands. Q2 tends to be a bit iffy, anyway. Much pessimism out there right now because of soft job #'s and Europe.
Apr 8, 5:54 PM
• !Report Abuse
Add a reply...

140 characters

Chines33
Favorite longs remain $MRK $PFE $HRB willing to add. Other longs I'm looking add starting/re adding:
Apr 3, 8:56 PM
Reply (4)

• !Report Abuse
View all 4 replies
Noreika: Glad to see you back Chines
Apr 4, 7:27 AM
• !Report Abuse
Chines33: Thanks.
Apr 4, 4:05 PM
• !Report Abuse
Add a reply...

140 characters

DAG1996
GE, PFE, CSCO, INTC, ORCL, MSFT, AKS, CHK & WTR - buy now or wait til after earnings? all opinions welcomed
1/17/12
Reply (28)

• !Report Abuse
View all 28 replies
Jim Warlick: I've seen a large amount of research on ORCL and largely expect them to achieve 10-15% earnings this year. Watch developing cloud tech. BUY
Feb 27, 2:55 PM
• !Report Abuse
madav1138: AKS 1.15 eps by 2015
Mar 16, 6:38 AM
• !Report Abuse
Add a reply...

140 characters

Joseph P. Porter
$DCIX, $FSC, $AMD, $ONTY, $PFE, $$RNO, $TCAP all up big time. $ONTY up 7.53% - about time people took advantage of big discount.
Feb 27, 3:01 PM
Reply (4)

• !Report Abuse
View all 4 replies
djamison: I know !!! Just when I was thinking things were are looking good !!
Mar 1, 9:03 AM
• !Report Abuse
Joseph P. Porter: They're good - it's just best to not pay attention to their stock price. $PFE is the best performing stock I have had long term, so I cope.
Mar 1, 11:10 AM
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
"Zoetis's 17 percent sales growth in 2011 outpaced all but Lilly's animal unit..." Wonder how big a stake Pfizer ($PFE) still has.
Feb 1, 11:39 AM
Reply (1)

• !Report Abuse
View all 1 replies
Deep Dives: I believe 82% of A-shares and 100% of B Shares.
Feb 6, 3:31 PM
• !Report Abuse
Add a reply...

140 characters

Joseph P. Porter
$PFE beats EPS and Revenue expectations hands down...I love my Drugs.
Jan 29, 11:09 AM
Reply (6)

• !Report Abuse
View all 6 replies
Joseph P. Porter: Whoa! Down > 80% in one sitting. This bears looking into - either something is seriously wrong, or this is one hell of a fine buying opp.
Jan 31, 2:25 PM
• !Report Abuse
Joseph P. Porter: Quick look tells me this is a bargain basement sale. Bought 200 shares $CLSN, will short it.
Jan 31, 2:34 PM
• !Report Abuse
Add a reply...

140 characters

Bob de'Long
If you're new here, click above on Market Currents to see the earnings come in $F $PFE etc.
Jan 29, 7:15 AM
Reply (3)

• !Report Abuse
View all 3 replies
Bob de'Long: Valero Energy $VLO) a petroleum refiner Q4 EPS of $1.82 beats by $0.59. Revenue of $34.7B (flat% Y/Y) beats by $3.69B.
Jan 29, 8:06 AM
• !Report Abuse
Bob de'Long: Peabody Energy $BTU): FQ1 EPS of -$1.12. Revenue of $2.01B beats by $0.08B. Stock is down 1% in pre-market
Jan 29, 8:09 AM
• !Report Abuse
Add a reply...

140 characters

PFE Pfizer Inc.

PFE

Pfizer Inc.